128 filings
Page 4 of 7
6-K/A
m2orx81008 p9fyylt
19 Jan 21
Current report (foreign) (amended)
6:25am
6-K
pobmh5mu
13 Jan 21
Current report (foreign)
4:00pm
6-K
okb6r 7pzxurvyq3ky
11 Jan 21
ObsEva Provides Update on Yselty® (Linzagolix) Clinical Development Program
7:05am
6-K/A
d9ft8ju ji
4 Jan 21
Current report (foreign) (amended)
6:36am
6-K
rei4vy55m9r95te2pi
4 Jan 21
ObsEva appoints David Renas as Chief Financial Officer
6:36am
6-K
s7yj brplwmr
10 Dec 20
Current report (foreign)
6:03am
6-K
5v47 u577g3l8nv2q2qm
24 Nov 20
Current report (foreign)
6:03am
6-K
itygst 78436pkcnk
16 Nov 20
ObsEva SA Reports Positive Topline Results of the PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
6:39am
6-K
rumfm9vz
9 Nov 20
ObsEva appoints Brian O’Callaghan as Chief Executive Officer
7:32am
6-K
xt5yhn9b7b4hocta
5 Nov 20
Index to Unaudited Condensed Consolidated Financial Statements
6:02am
6-K
enx19upsgxiki5
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am
6-K
98y gpv4csp
14 Aug 20
Current report (foreign)
4:24pm
6-K
mmxoa3ed
6 Aug 20
Index to Unaudited Condensed Consolidated Financial Statements
6:53am
6-K
wlq2npzjt8lypctes9
7 Jul 20
Current report (foreign)
3:39pm
6-K
7ctc1h9lmj 8ysy8q
6 Jul 20
ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids
6:18am
6-K
4htuwuulzoz sdnx0
1 Jul 20
ObsEva and Yuyuan BioScience Technology Announce Submission of the Pre-IND Dossier for Nolasiban with the Chinese NMPA
6:15am
6-K
usefxrq6 vsvr
9 Jun 20
Current report (foreign)
4:10pm
6-K
yyadj
4 Jun 20
ObsEva Announces Publication of Data Showing Efficacy of Linzagolix in a Potential New Indication for Treatment of Adenomyosis
6:11am
6-K
bz87r5pi3dhq3oby942
8 May 20
ObsEva Annual General Meeting 2020
4:38pm
6-K
epac lv6q
5 May 20
Index to Unaudited Condensed Consolidated Financial Statements
6:01am